<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507635</url>
  </required_header>
  <id_info>
    <org_study_id>535</org_study_id>
    <nct_id>NCT02507635</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory H1 Antihistamines Allergic Rhinitis</brief_title>
  <official_title>In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the treatment of persistent allergic rhinitis is to improve symptoms and&#xD;
      patients' quality of life and prevent the development of asthma. Therapeutic strategies also&#xD;
      target a reduction of pro-inflammatory mediators released from activated cells, including&#xD;
      mast cells and epithelial cells. The presence of allergic inflammation in nasal mucosa may&#xD;
      increase the risk of asthma occurrence, especially in patients with persistent allergic&#xD;
      rhinitis. H1 antihistamines are widely recommended in all types of allergic rhinitis,&#xD;
      regardless of symptom severity or persistence. They control all of the symptoms, but to a&#xD;
      lesser extent nasal congestion. New generation agents, such as levocetirizine and&#xD;
      desloratadine, possess anti-inflammatory properties, reducing allergic inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a&#xD;
      risk factor for asthma occurrence. H1 antihistamines reduce the rhinitis' symptoms, but some&#xD;
      compounds may have anti-inflammatory properties.&#xD;
&#xD;
      We evaluated the plasmatic level of some cytokines in patients with persistent allergic&#xD;
      rhinitis (PAR) and their evolution after 4-week treatment with H1 antihistamines and the risk&#xD;
      of asthma after 1.5 year.&#xD;
&#xD;
      Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The&#xD;
      patients with PAR were randomly divided into 2 groups: 41 patients treated with desloratadine&#xD;
      5 mg/day and 44 patients under levocetirizine 5 mg/day for 4 weeks.&#xD;
&#xD;
      The clinical evaluation include the presence and severity of allergic rhinitis' symptoms:&#xD;
      rhinorrhea, nasal congestion, sneezing, nasal and ocular itching and duration of the disease.&#xD;
&#xD;
      Each symptom was evaluated on scale from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe) and&#xD;
      after that we calculated the total symptoms score (TSS).&#xD;
&#xD;
      A TSS&lt;6 means a mild rhinitis, while a TSS&gt; 6 represented a moderate severe one.&#xD;
&#xD;
      The patients were clinically evaluated after 1.5 year to determine the possible onset of&#xD;
      bronchial asthma.&#xD;
&#xD;
      The biological evaluation means determination of total IgE and plasmatic level of IL-1 beta,&#xD;
      IL-6, IL-8 and TNF alpha.&#xD;
&#xD;
      Clinical and biological evaluation were performed before and after treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of H1 antihistamines (patients evaluation)</measure>
    <time_frame>4 weeks</time_frame>
    <description>patients evaluation before and after 4-weeks treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>asthma risk (incidence of asthma in patients with persistent allergic rhinitis after 1.5 years from study inclusion)</measure>
    <time_frame>1.5 years</time_frame>
    <description>incidence of asthma in patients with persistent allergic rhinitis after 1.5 years from study inclusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levocetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine</intervention_name>
    <description>administration of Levocetirizine 5 mg/day for 4 weeks</description>
    <arm_group_label>Levocetirizine</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine</intervention_name>
    <description>administration of Desloratadine 5 mg/day for 4 weeks</description>
    <arm_group_label>Desloratadine</arm_group_label>
    <other_name>Aerius</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persistent allergic rhinitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the presence of asthma or nasal polyps,&#xD;
&#xD;
          -  acute and chronic upper respiratory infections,&#xD;
&#xD;
          -  administration of intranasal or systemic corticosteroids or H1 antihistamines in the&#xD;
             past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Stefan Cristian Vesa</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>cytokines</keyword>
  <keyword>persistent allergic rhinitis</keyword>
  <keyword>H1 antihistamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

